Posts in Pharmaceutical Companies.
| BLOG

On January 17, 2013, the Federal Trade Commission (FTC) issued a report revealing an increase in “pay-for-delay” or “reverse-payment” patent settlements between brand-name pharmaceutical companies and their generic counterparts

These controversial settlements typically involve a brand-name drug manufacturer who is granted a drug patent which gives the company the exclusive right to sell the drug for up to 20 years, depending on the type of drug. The patent is then challenged by a generic rival.  Rather than risk losing their patent monopoly on account of a judgment ...

Search Blog

Categories

Archives

Contact

Kerri Forsythe
618.307.1150
Email

Jump to Page

This website uses cookies to analyze site usage and to store information about a visitors' session. These cookies allow us to distinguish you from other visitors of our website. We use these cookies purely for analytical purposes and for our own statistical research into the success of our website.

We Encourage You To View Our PRIVACY STATEMENT